CRYSTAL
2009
Cetuximab + FOLFIRI in Metastatic Colorectal Cancer
In 1,198 patients with untreated metastatic colorectal cancer, cetuximab + FOLFIRI improved PFS in the KRAS/RAS wild-type subgroup compared with FOLFIRI alone.
Result
Efficacy: Progression-free survivalHR 0.7
Below 1 favours cetuximab + FOLFIRI, above 1 favours FOLFIRI alone.
Event rates Cetuximab + FOLFIRI 9.9 vs FOLFIRI alone 8.4 months
Also reported: OS 23.5 vs 20.0 months (HR 0.80). Post-hoc RAS WT: OS 28.4 vs 20.2 months (HR 0.69).
- Subtopic
- mCRC anti-EGFR
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Van Cutsem E, et al. N Engl J Med. 2009;360(14):1408-1417; Van Cutsem E, et al. J Clin Oncol. 2011;29(15):2011-2019.doi 10.1056/NEJMoa0805019
Discussion & critique
Mandated KRAS/RAS testing before anti-EGFR therapy. Sidedness also matters: anti-EGFR is preferred for left-sided RAS-WT disease.